These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11462924)

  • 61. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
    Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
    Park JS; Oh SY; Kim SH; Kwon HC; Kim JS; Jin-Kim H; Kim YH
    Jpn J Clin Oncol; 2005 Feb; 35(2):68-73. PubMed ID: 15709089
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.
    Salimon M; Prieux-Klotz C; Tougeron D; Hautefeuille V; Caulet M; Gournay J; Matysiak-Budnik T; Bennouna J; Tiako Meyo M; Lecomte T; Zaanan A; Touchefeu Y
    Br J Cancer; 2018 Feb; 118(3):325-330. PubMed ID: 29169182
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Unresectable combined hepatocellular-cholangiocellular carcinoma treated with transcatheter arterial chemoembolization and gemcitabine: a case study].
    Sano T; Ishikawa T; Imai M; Owaki T; Sato H; Nozawa Y; Iwanaga A; Seki K; Honma T; Yoshida T; Nishikura K; Ishihara N; Kamimura T
    Nihon Shokakibyo Gakkai Zasshi; 2018; 115(12):1069-1077. PubMed ID: 30531113
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
    Li J; Merl M; Lee MX; Kaley K; Saif MW
    Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
    Tomao S; Romiti A; Massidda B; Ionta MT; Farris A; Zullo A; Brescia A; Santuari L; Frati L
    Anticancer Res; 2002; 22(4):2361-4. PubMed ID: 12174927
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.
    Naqi N; Ahmad S; Murad S; Khattak J
    Hematol Oncol Stem Cell Ther; 2014 Mar; 7(1):27-31. PubMed ID: 24333135
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.
    Sprinzl MF; Schimanski CC; Moehler M; Schadmand-Fischer S; Galle PR; Kanzler S
    BMC Cancer; 2006 Jul; 6():190. PubMed ID: 16846514
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer.
    Tsavaris N; Kosmas C; Gouveris P; Gennatas K; Polyzos A; Mouratidou D; Tsipras H; Margaris H; Papastratis G; Tzima E; Papadoniou N; Karatzas G; Papalambros E
    Invest New Drugs; 2004 Apr; 22(2):193-8. PubMed ID: 14739669
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma.
    Charoentum C; Thongprasert S; Chewaskulyong B; Munprakan S
    World J Gastroenterol; 2007 May; 13(20):2852-4. PubMed ID: 17569122
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
    Ang SF; Tan SH; Toh HC; Poon DY; Ong SY; Foo KF; Choo SP
    Am J Clin Oncol; 2012 Jun; 35(3):222-7. PubMed ID: 21378539
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
    Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
    Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK
    J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study.
    Lombardi G; Zustovich F; Farinati F; Cillo U; Vitale A; Zanus G; Donach M; Farina M; Zovato S; Pastorelli D
    Cancer; 2011 Jan; 117(1):125-33. PubMed ID: 21058409
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
    Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H
    J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Radiochemotherapy with Gemcitabine in Unresectable Extrahepatic Cholangiocarcinoma: Long-term Results of a Phase II Study.
    Autorino R; Mattiucci GC; Ardito F; Balducci M; Deodato F; Macchia G; Mantini G; Perri V; Tringali A; Gambacorta MA; Tagliaferri L; Giuliante F; Morganti AG; Valentini V
    Anticancer Res; 2016 Feb; 36(2):737-40. PubMed ID: 26851032
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial.
    Liu B; Huang JW; Li Y; Hu BS; He X; Zhao W; Zheng YB; Lu LG
    Oncology; 2015; 89(1):23-30. PubMed ID: 25613214
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Gemcitabine transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma.
    Hammond JS; Franko J; Holloway SE; Heckman JT; Orons PD; Gamblin TC
    Hepatogastroenterology; 2014; 61(133):1339-43. PubMed ID: 25436307
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival.
    Schiffman SC; Metzger T; Dubel G; Andrasina T; Kralj I; Tatum C; McMasters KM; Scoggins CR; Martin RC
    Ann Surg Oncol; 2011 Feb; 18(2):431-8. PubMed ID: 20862554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.